Press Releases MBX Biosciences, Inc.

Equities

MBX

US55287L1017

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-21 pm EDT			5-day change	1st Jan Change
33.24 ^USD	-1.60%		+1.31%	+5.39%

Mar. 16	Mbx Biosciences Insider Bought Shares Worth $525,663, According to a Recent SEC Filing	MT
Mar. 12	MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI

Press Releases

Apr. 03	MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
Mar. 12	MBX Biosciences : Company Overview - March 2026	PU
Mar. 12	MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights	AQ
Mar. 10	MBX Biosciences Appoints Karen Basbaum as Chief Business Officer	AQ
Mar. 09	MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism	AQ
Feb. 23	MBX Biosciences to Participate in Upcoming March Investor Conferences	AQ
Feb. 11	MBX Biosciences to Participate in Upcoming Investor Conferences	AQ
Jan. 22	MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair	AQ
Jan. 13	MBX Biosciences : Company Overview - January 2025	PU
Jan. 11	MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference	AQ
Dec. 15	MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13	AQ
Nov. 18	MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference	AQ
Nov. 06	MBX Biosciences : Company Overview - November 2025	PU
Nov. 06	MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights	AQ
25-10-20	MBX Biosciences to Participate in November Investor Conferences	AQ
25-09-29	MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum	AQ
25-09-24	MBX Biosciences Announces Pricing of Upsized Public Offering	AQ
25-09-22	MBX Biosciences Announces Proposed Public Offering	AQ
25-09-22	MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension	AQ
25-09-19	MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22	AQ
25-09-04	MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity	AQ
25-08-07	MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights	AQ
25-06-23	MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development	AQ
25-06-16	MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity	AQ
25-06-10	MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions	AQ